Adjuvance Technologies

Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships.


The next generation semi-synthetic saponin adjuvants are used to prevent and treat infectious diseases, and in immuno-oncology, neurobiology, substance abuse, and allergy.  Our first adjuvant, TQL-1055, has increased vaccine immunogenicity and favorable tolerability in a clinical trial. Our vaccine candidates in pertussis and herpes zoster aim to provide a better experience for the recipient and the same protection against disease.

Adjuvance Headquarters

Adjuvance News

Keep up with the latest news about Adjuvance Technologies, including news releases, development updates, and more.

Adjuvance Technologies to Present at 2021 Bio Digital

Lincoln, NE – June 11, 2021 – Adjuvance Technologies Inc. announced today that it has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 & 14-18, 2021. J. Tyler Martin MD, CEO and...